Domestic price of Sarilumab

Sarilumab is a human IgG1 monoclonal antibody that specifically binds to soluble and membrane-bound IL-6Rs (sIL-6Rα and mIL-6Rα) and has been shown to inhibit IL-6-mediated signaling through these receptors. In two previous Phase III trials, salirumab administered subcutaneously at 150 and 200 mg every 2 weeks (Week 2) was effective in several rheumatoid arthritis (RA) patient groups, including those who had an inadequate response to MTX and those who had an inadequate response to or intolerance to TNF inhibitors.

The addition of salivolumab inhibited radiographic progression in patients with inadequate responders to MTX and, in both studies, achieved rapid and sustained improvement in disease activity and improved physical function with a manageable safety and tolerability profile consistent with IL-6R blockade. The safety and tolerability profile of salivolumab was consistent across studies and comparable to therapeutic targeting of the IL-6 pathway. Changes in laboratory values u200bu200bincluded neutropenia, liver transaminases, and total cholesterol. Studies have shown that blocking IL-6R does not affect neutrophil function and that reduced neutrophil counts are not associated with increased rates of concurrent infections.

The patent drug of Salirutumab is a new type of drug for treating diseases. It has not yet been launched in China, so it is not covered by medical insurance. Patients cannot yet purchase this drug in domestic hospitals or pharmacies. The common dosage form of Salirutumab's original drug is injection, which has been marketed overseas. The price of the European version of the specification200mg*2 per box is around 17,500 (the price may fluctuate due to the exchange rate). There are currently no generic Salirutumab produced in other countries.